Summary NR 565 Final Exam Study Guide

CYP450 Ienzyme IGI Iinteractions: ICimetidine IH2 Ireceptor Iantagonist, IOmeprazole IPPI, IAlosetron I(IBS-D) H. IPylori ITesting: Iconsider Iif Ipatient Ihas IGERD Iabdomen Ipain Iunresolved, Istarting Iaspirin Itherapy, Istomach Ior Iduodenal Iulcer, Iafter Itreatment Ifor Ih. Ipylori H. IPylori ITreatment: I10-14 Iday Iantibiotic Itherapy, IPPI Ior IH2 Preferred Itherapy: Ilow Iresistant Iregion Iclarithromycin-based Itriple Itherapy I(clarithromycin, Iamoxicillin, IPPI). I**PCN Iallergy, Iuse Imetronidazole Ias Isubstitute. High Iresistant Iregion Ibismuth-based Iquadruple Itherapy I(bismuth, Iflagyl, Itetracyline, Iwith IPPI Ior IH2RA. If Ipatients Iunable Ito Itake Iall Itherapies Iat Ione Itime, Isequential Itherapy Iis Ioption. IPPI Iplus Iamox I5 Idays, Ithen IPPI Iplus Iclarithromycin Iand Itinidazole I5 Idays. Lifestyle IHabits: Ismoking Icessation, Iavoid INSAIDS, Ibland Ifoods. IBS: Iabd Ipain Ior Idiscomfort Ithat Icannot Ibe Iexplained Istructurally Ior Ichemically Ifor I12 Iweeks Ior Imore Iand Ihas Ipain Ir/t Idefecation, Ichange Iin Ifreq Ior Iconsistency Iof Istool. psyllium Ifiber, Iprobiotics/prebiotics, Iantibiotics I(rifaximin), Iantispasmodics I(hyoscyamine, Idicyclomine), ITCA Iantidepressants, IIBS-D Iloperamide, ITCA IBS-D I:Alosetron I(Lotronex I– IGI Itoxicity, Inot Iapproved Iin Imen), IEluxadoline I(Viberzi) IBS-C: ILubriprostone I(Amitiza), ILinaclotide I(Linzess)